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Hepatocellular carcinoma (HCC) is one of the most prevalent tumors worldwide. Interferon-𝛼 (IFN-𝛼) has been widely used in
the treatment of HCC, but patients eventually develop resistance. ISG15 ubiquitin-like modifier (ISG15) is a ubiquitin-like protein
transcriptionally regulated by IFN-𝛼 which shows antivirus and antitumor activities. However, the exact role of ISG15 is unknown.
In the present study, we showed that IFN-𝛼 significantly induced ISG15 expression but failed to induce HepG2 cell apoptosis,
whereas transient overexpression of ISG15 dramatically increased HepG2 cell apoptosis. ISG15 overexpression increased overall
protein ubiquitination, which was not observed in cells with IFN-𝛼-induced ISG15 expression, suggesting that IFN-𝛼 treatment
not only induced the expression of ISG15 but also inhibited ISG15-mediated ubiquitination. The tumor suppressor p53 and p21
proteins are the key regulators of cell survival and death in response to stress signals such as DNA damage. We showed that p53 or
p21 is only up regulated in HepG2 cells ectopically expressing ISG15, but not in the presence of IFN-𝛼-induced ISG15. Our results
suggest that ISG15 overexpression could be developed into a powerful gene-therapeutic tool for treating IFN-𝛼-resistant HCC.

1. Introduction
Hepatocellular carcinoma (HCC) is one of the most prevalent
tumors worldwide and a major threat to our modern life [1].
Although different therapies are available, interferon-𝛼 (IFN𝛼) is considered one of the treatments of choice for patients
with hepatic cancer. IFN-𝛼 not only retards cancer cell
growth by inhibiting angiogenesis and proliferation, but also
it modulates the immune response and promotes apoptosis.
However, patients often develop resistance to IFN-𝛼, and
the mechanisms of resistance are unknown. Therefore, the
development of efficient strategies for overcoming resistance
to IFN-𝛼 in HCC patients is essential [2].
IFN-𝛼 signaling pathway, which has been studied extensively, is activated by the phosphorylation of Janus kinase 1
(JAK1) and tyrosine kinase 2 (TYK2), which activates the
downstream signal transducer and activator of transcription 1 (Stat1) and Stat2, leading to the formation of the
transcriptional complex ISG factor 3 (ISGF3) [3]. ISGF3
upregulates the expression of a wide spectrum of genes which
contain the IFN-𝛼-stimulated response elements (ISREs) in
their promoters [4, 5]. ISG15 is a ubiquitin-like protein

whose expression is induced by IFN-𝛼 treatment [6]. Protein
modification by ISG15 is known as ISGylation and occurs
through sequential reactions similar to ubiquitination. Ubiquitination is a type of protein modification that consists
of the attachment of ubiquitin to specific lysine residues
of the target substrate. Proteins can be mono-, multi-, or
polyubiquitinated, and poly-ubiquitination usually leads to
protein degradation via the 26S proteasome system [7, 8].
ISGylation, which affects the stability, subcellular localization
and function of the modified proteins, is mediated by an E1
activating enzyme (Ube1l), E2 conjugating enzymes (UbcH8,
UbcH6), and E3 ligases (EFP) [9–11]. Hundreds of proteins
have been identified as targets of ISGylation, and protein
modification by ISGylation has been widely shown to be
involved in the regulation of different biological processes
included in cancer development and therapy [12].
Although both ISG15 and the ISGlyation enzymes are
regulated by IFN-𝛼, the effects of ISG15 and ISGlyation
on IFN-𝛼 therapy and their roles in IFN-𝛼 resistance are
unknown. We used the HepG2 cell line as a model system to
study the effects of ISG15 expression on cancer cell apoptosis.
As HepG2 cells express the wild-type form of the tumor

2
suppressor p53 [13], this model system also allowed us to
detect the effects of ISG15 on p53 and its downstream protein
p21, both of which play the key regulatory roles in cell survival
or cell death [14, 15].
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2. Materials and Methods
2.1. Cell Culture and IFN-𝛼 Treatment. HepG2 cells were
cultured in RPMI1640 medium (Invitrogen, USA) supplemented with 10% fetal bovine serum (Sijiqing Biological
Engineering Materials Co., Ltd., China) at 37∘ C in an atmosphere with 5% CO2 . IFN-𝛼 treatment was performed in 5 mL
growth medium with different concentrations (0, 500, 1000,
and 2000 U/mL) of IFN-𝛼 for 48 h.
2.2. Plasmid Construction and Transfection. Human
ISG15 (Gene ID: 9636) cDNA was made by the reverse
transcriptase reaction from total RNA extracted from IFN𝛼-treated human chronic myeloid leukemia cell line KT1-A3
cells. The PCDNA3.1-ISG15 plasmid was constructed by
inserting the ISG15 cDNA amplified by RT-PCR (upstream
primer: CTTGGTACCGCAGCGAACTCATCTTTG and
downstream primer: GGAGGATCCTCTTTACAACAGCCTTTATTTC) into the PCDNA3.1 plasmid (Invitrogen,
NY, USA). The constructed plasmid was sequenced by
BGI (a genomic research company, Beijing, China; web link:
http://www.genomics.cn/en/index). HepG2 cells were seeded
in 6-well plates (3 × 105 cells/well) and transfected using
Sofast Transfection Reagent (Sunma Biotech Corp., Xiamen,
China). The medium was replaced by fresh RPMI1640 after
6 h and incubated for 12 h followed by further experiments.
2.3. Western Blotting Analysis. The harvested cells were lysed
by cold RIPA buffer (200 𝜇L/well, Beyotime Institute of
Biotechnology Corp., Shanghai, China) supplemented with
1 mM proteinase inhibitor PMSF (Beyotime Insititute of
Biotechnology Corp., Shanghai, China) for 30 min on ice,
and then centrifuged at 15000 g for 15 min. The supernatant
containing proteins were stored at −20∘ C. The protein concentration was determined by the Bradford assay. Proteins
were separated by sodium dodecyl sulphate-polyacrylamide
gel electrophoresis (SDS-PAGE). After electrophoresis, proteins were transferred to nitrocellulose membrane by electroblotting and blocked in TBST (50 mM Tris-HCl, pH 7.5,
150 mM NaCl, 0.2% Tween-20) containing 5% nonfat milk
for 2 h at room temperature. The blots were incubated with
the primary antibody (1 : 1000) at 4∘ C overnight and washed
with TBST three times. Then, the blots were incubated with
the secondary antibody (1 : 5000) at room temperature for 1 h.
All the antibodies used in this study (ISG15, p53, ubiquitin,
𝛽-actin, and horseradish peroxidase-conjugated secondary
antibodies) were purchased from Cell Signaling Technology,
USA.
2.4. Subcellular Localization by Confocal-Scanning Laser
Microscopy. The cells with different treatments were fixed in
4% paraformaldehyde and permeabilized with 0.1% TritonX100 in PBS containing 1% BSA for 10 min. The washed cells
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Figure 1: Expression of ISG15 in HepG2 cells. HepG2 cells were
treated with different concentrations of IFN-𝛼 for 48 h. ISG15
expression was detected by western blotting using anti-ISG15 antibody.

were then blocked in PBS containing 10% BSA at 37∘ C for
30 min and incubated with ISG15 primary antibody (1 : 50)
at 4∘ C overnight. The cells were then washed with PBS and
incubated with Cy5-labeled secondary antibody (1 : 100) at
room temperature for 1 h. After washing again, the cells were
dyed by DAPI and watched by using confocal-scanning laser
microscopy.
2.5. Flow Cytometric Analysis. Cells were collected, washed
twice with PBS (pH 7.4), and fixed in 70% ethanol overnight.
Then, the fixed cells were washed with 1 mL of PBS.
Then 500 𝜇L of PBS containing 3, 8-diamino-5-[3-(diethylmethylammonio)propyl]-6-phenylphenanthridinium diiodide (PI, 50 𝜇g/mL) and RNase A (100 𝜇g/mL) was added
at 37∘ C in dark room. After 30 min, the cells were analyzed
by Cytomics FC500 (Beckman Coulter, USA). The data were
collected by the software of CXP, and results were analyzed
by ModFit LT. Flow cytometric analysis was performed by
DingGuo Company (Beijing DingGuo ChangSheng Biotechnology Co., Ltd., China).
2.6. Statistical Analysis. Densitometry of western-blot bands
were quantified by ImageJ software. Data were analyzed by
one-way ANOVA and post hoc (least significant difference)
LSD test. The statistical program SPSS 16.0 was used for the
analysis, and the graphs were generated in MS Excel. Results
were presented as mean ± SD (standard deviation). The star
marker “∗ ” indicates significant difference compared with
control at 𝑃 ≤ 0.05 level.

3. Results
3.1. IFN-𝛼 Induces ISG15 Expression in HepG2 Cells. HepG2
cells were treated with different concentrations of IFN-𝛼 for
48 h, and ISG15 levels were detected by western blotting (The
experiment was repeated 3 times). As shown in Figure 1,
ISG15 was undetectable in untreated HepG2 cells (control),
and its levels were increased in response to IFN-𝛼 treatment, although a concentration-dependent effect (500 U/mL;
1000 U/mL; 2000 U/mL) was not observed. A dosage of
1000 U/mL of IFN-𝛼 was used in the subsequent experiments
based on the commonly used dosage in clinical practice.
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Figure 2: ISG15 overexpression induced ISGylation and ubiquitination and increased p53 levels (a) ISGylation and ubiquitination were
detected by western blotting. HepG2 cells treated with IFN-𝛼 or transiently transfected with different plasmid were cultured for 48 h, and
protein expression was assessed by western blotting. (b) p53 expression was examined by western blotting using anti-p53 antibody in cells
treated with different factors for 48 h. (c) Densitometry of Western blotting bands was quantified by using ImageJ software (gray-scale band
analysis). Data were analyzed by one-way ANOVA and post hoc LSD test. Results are shown as mean ± SD (𝑛 = 4). ∗ 𝑃 ≤ 0.05 compared with
control HepG2 cells.

3.2. Effects of ISG15 on p53 and p21 Expression and Protein Ubiquitination. The increase of the levels of ISG15 in
response to both IFN-𝛼 induction and transient transfection
of cells with PCDNA3.1-ISG15 plasmid led us to examine
whether ISGlyation was affected under these conditions. We
quantified ISGylation, ubiquitination, and p53 and p21 levels
for 4 times. Each time we recovered a new tube of HepG2
cells stored in our lab and cultured for experiments. Then,
we added the IFN-𝛼 or transiently transfected PCDNA3.1ISG15 and control PCDNA3.1 to divided cell independently.

The statistical data of the densitometry of relative protein
ratio of ISGylation/𝛽-acitin, ubq/𝛽-acitin, p53/𝛽-acitin, and
p21/𝛽-acitin were used to identify whether the target proteins
expression was changed (Figure 2(c)).
Overall protein ISGlyation was assessed by western blotting using specific antibody against ISG15. As shown in
Figure 2(a), a basal level of protein ISGlyation was detected
in the HepG2 cell lysate (Lane 1), which increased dramatically when the cells were treated with IFN-𝛼 (Lane 2)
or transiently transfected with PCDNA3.1-ISG15 (Lane 4).

4
Transient transfection of cells with the empty plasmid vector
PCDNA3.1 had no effect on protein ISGlyation (Lane 3).
Because of the similarity between ISGlyation and ubiquitination, we also analyzed the overall ubiquitination status
in HepG2 cells treated with IFN-𝛼 and in those transfected
with the PCDNA3.1-ISG15 plasmid. As shown in Figure 2(a),
compared with the basal levels of protein ubiquitination
(Lane 1), IFN-𝛼-induced ISG15 also increased protein ubiquitination (Lane 2), but it had no statistical significance when
compared with control HepG2 cells. On the other hand,
transient overexpression of ISG15 dramatically increased
protein ubiquitination (Lane 4). Transfection of cells with the
empty plasmid vector had no effect on protein ubiquitination
(Lane 3). Equal protein loading was confirmed by probing
membranes against an antiactin antibody. Taken together, our
results indicated that ectopically overexpressed ISG15 had a
different effect compared with IFN-𝛼-induced ISG15. Since
p53 is one of the most important tumor suppressors involved
in the regulation of tumor cell apoptosis, we investigated
whether transiently expressed ISG15 and IFN-𝛼 induced
ISG15 had different effects on p53 and p53 downstream
protein p21. The expression levels of the p53 and p21 proteins
were determined by western blot assay using a specific antip53 or anti-p21 antibody. As shown in Figure 2(b), p53 and
p21 protein levels in the cells treated with IFN-𝛼 (Lane 2) were
comparable to those of untreated controls (Lane 1) and cells
transfected with the empty plasmid vector (Lane 3). However,
cells overexpressing ISG15 by transient transfection of the
PCDNA3.1-ISG15 vector showed significantly increased p53
and p21 levels (Lane 4). The gray scale protein bands intensity
from 4-time experiments was quantified by ImageJ software.
Data were analyzed by one-way ANOVA and post hoc LSD
test (Figure 2(c)). These results indicated that the upregulation of p53 and p21 expression was specific to the HCC cells
with ectopically overexpressed ISG15.
3.3. Subcellular Localization of ISG15 in HepG2 Cells. Protein
ISGylation plays an important role in the regulation of many
cellular pathways, but the exact function and localization
of ISG15 and ISG15 modifier proteins are unclear [16]. We
used confocal-scanning laser microscopy to determine the
subcellular localization of ISG15 in HepG2 cells after 48 h
culture. Consistent with the results of western blotting, ISG15
and ISGylated proteins were not detectable in HepG2 cells
without IFN-𝛼 treatment, and the empty plasmid vector
transfection had also no effect on ISG15 expression (Figure 3).
However, ISG15 was clearly detected when the cells were
treated with IFN-𝛼 or transfected with the PCDNA3.1-ISG15
plasmid. Furthermore, ISG15 localized in both the nucleus
and the cytoplasm (Figure 3) suggesting that ISG15 may
function in both nucleus and cytoplasm.
3.4. Overexpression of ISG15 Inhibits HepG2 Cell Growth.
Proteasome inhibitors such as MG132 can increase the level
of protein ubiquitination and cell apoptosis [17]. Therefore, we investigated whether overexpressed ISG15 had an
effect on IFN-𝛼 resistance and possibly enhanced cancer
cell apoptosis by upregulating protein ubiquitination. Flow
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cytometry was used to determine the distribution of cells in
different stages of the cell cycle and detect apoptotic cells.
As shown in Figure 4, the percentage of cells in the S phase
was 52.17% in control HepG2 cells, 48.5% in IFN-𝛼-treated
HepG2 cells, and 55.12% in HepG2 cells transfected with the
empty plasmid vector. However, up to 82.94% of cells were
in the S phase when ISG15 was transiently overexpressed,
suggesting that ISG15 overexpression inhibits HepG2 cell
growth by inducing S phase arrest. Furthermore, 0.78% and
2.59% of apoptotic cells were detected in control and empty
vector transfected cells, respectively, while induction of ISG15
expression by IFN-𝛼 treatment increased the proportion of
apoptotic cells to 5.21%, and overexpression of ISG15 by
transient transfection induced apoptosis in 13.21% of HepG2
cells. This single determination indicated that transiently
overexpressed ISG15 was more efficient than that induced by
IFN-𝛼 for cell cycle regulation and induction of apoptosis in
HepG2 cells, and this explained that the growth of HepG2
cells transfected with ISG15 was slower than the cells treated
with IFN-𝛼 or transfected with control plasmid observed by
microscope.

4. Discussion
IFN-𝛼, as a therapeutic reagent with antitumor properties,
has been widely used in combination with other drugs against
many malignancies including HCC. However, the clinical
outcomes of IFN-𝛼 therapy have not been satisfactory [18].
More importantly, resistance to IFN-𝛼 therapy among HCC
patients has been reported frequently [19], and the underlying
mechanisms of IFN-𝛼 resistance remain unclear. There are
different reasons for IFN-𝛼 resistance in HCC. For example,
mutation or deletion of the IFN alpha receptor 2 (IFNAR2)
can lead to the alterations of IFN-𝛼-mediated transcription,
which ultimately causes the IFN-𝛼 resistance [20]. Also, there
are some reports that indicate the IFN-𝛼 function independent of IFNAR2. Transcriptional alteration of some genes
may cause IFN-𝛼 resistance too [21]. Moreover, the activation
of WNT/𝛽-catenin pathway also has role on IFN-𝛼 resistance
in HCC [22]. ISG15 as well as the enzymes involved in ISGylation are upregulated by IFN-𝛼 presumably through the ISREs
in their promoter regions. In the present study, we aimed
to gain a better understanding of the anticancer function of
IFN-𝛼 and its targeted gene ISG15. In order to bypass the
complex network of IFN-𝛼-regulated pathway, we ectopically
overexpressed ISG15 in HepG2 cells by transient transfection.
This strategy enabled us to compare the similarities and differences between the overexpressed ISG15 and ISGylation in
HepG2 cells and that induced by IFN-𝛼 treatment. Combined
with the well-established functions of some molecules, such
as ISG15, protease Ubp43 triggered by IFN-𝛼 could reverse
the functions of IFN-𝛼 by inhibiting the STAT pathway
[23]. We prove that IFN-𝛼-induced ISG15 did not have an
anticancer function, whereas transiently overexpressed ISG15
significantly inhibited HepG2 cell growth and enhanced cell
apoptosis. Although these experiments were conducted in
HCC cells, the results may be applicable to other IFN-𝛼resistant malignancies and may be helpful to the design of
efficient therapeutic strategies for IFN-𝛼-resistant carcinoma.
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Figure 3: Subcellular localization of ISG15 in HepG2 cells. Free ISG15 and ISG15 modified proteins were detected by confocal-scanning laser
microscopy at a magnification of 100x using anti-ISG15 antibody and Cy5-labeled secondary antibody. The Cy5 wavelength was detected by
a confocal-scanning laser microscope and is shown in red, while nuclei were stained by DAPI and are shown in blue.

ISG15 has two functional domains, the N-terminal and
the C-terminal domains which bear 33% and 32% sequence
similarity to ubiquitin, respectively [10]. Both protein ubiquitination and ISGylation processes are the same and can
share some common enzymes. The levels of ISGylation
and ubiquitination are dynamically regulated by the addition and removal of modifier enzymes. The enzymes such
as Usp2, Usp5, Usp13, and Usp14 are responsible for deISGylation and de-ubiquitination [24]; however, Ubp43 is

only responsible for the removal of ISG15 from ISGylated
targets. Because some modifier enzymes can be induced
by IFN-𝛼, our results showing different effects of IFN-𝛼induced or transiently transfected ISG15 could be dependent
on the expression of ISG15 modifier enzymes. IFN-𝛼 is
capable of inducing de-ISGylation enzyme expression and
reversing the biological function of ISG15. In the absence
of IFN-𝛼-induced de-ISGylation enzyme expression, ISG15
increases protein ubiquitination and ISGylation (Figure 2).

6
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Figure 4: Apoptosis in HepG2 cells under different conditions. HepG2 cells either treated with IFN-𝛼 (1000 U/mL), transfected with
PCDNA3.1, PCDNA3.1-ISG15, or control HepG2 cells were cultured for 48 h. Harvested cells were fixed and treated with 500 𝜇L PBS
containing 50 𝜇g/mL PI and 100 𝜇g/mL RNase A at 37∘ C avoiding light for 30 min. Apoptosis and cell cycle progression were analyzed by
flow cytometry (single determination).

Therefore, overexpression of ISG15 may affect protein ISGylation directly and protein ubiquitination indirectly. Ubiquitinated proteins play critical roles in various cellular processes
such as protein degradation, cell cycle regulation, and DNA
replication [25, 26]. Polyubiquitination targets proteins for
degradation via the ubiquitin proteasome pathway (UPP),
which is a method of eliminating misfolded or damaged
proteins in eukaryotes [8]. Blocking the UPP results in the
accumulation of ubiquitinated proteins and was shown to
inhibit tumorigenesis. Our results indicate that overexpressed
ISG15 can increase protein ISGylation and ubiquination,
but the IFN-𝛼 cannot increase the protein ubiquination
(Figure 2). These results together with the finding that HCC
cell apoptosis was increased only in the cells overexpressing
ISG15 (Figure 4) suggest that ISG15 acts by a combination

of these effects and its proapoptotic role is mediated by the
induction of the accumulation of ubiquitinated proteins.
The p53 is a short-lived protein that is degraded by
the UPP [27]. As a key regulator protein, p53 determines
cell fate under diverse stress conditions [14]. We examined
the possible involvement of p53 in HepG2 cell apoptosis
induced by ISG15 overexpression by estimating the levels of
the p53 protein in different experimental settings. As shown
in Figure 2(c), p53 levels were clearly elevated in HepG2
cells when ISG15 was overexpressed by transient transfection.
Although ISG15 levels in response to IFN-𝛼 induction and
transient transfection were comparable, ISG15 upregulated by
IFN-𝛼 treatment failed to modulate p53 levels. The fact that
p53 can be modified by ubiquitin [28] together with our findings that overexpression of ISG15 enhanced ubiquitination
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and apoptosis suggest that overexpression of ISG15 increases
cancer cell apoptosis through a p53-dependent pathway. The
p21 is the most important downstream protein regulated by
the activated p53, which can directly inhibit cell growth,
increase apoptosis, and cause cell cycle arrest at S phase [29].
As shown in Figure 2(b), the p21 expression was increased
in the cells with ISG15 transient transfection, and it caused
HepG2 cell apoptosis and S phase arrest (Figure 4). However,
there were multiple factors involved in regulating the cellular
levels of p53 and p21; therefore, we cannot ascertain that
the changes in p53 or p21 levels in our study were directly
caused by the overexpressed ISG15. Mechanistically, ectopic
overexpression of ISG15 can bypass the pluripotent effects
of IFN-𝛼 and upregulate p53 and p21 as well as increase
HepG2 cell apoptosis efficiently. Although the molecular
mechanisms underlying the anticancer effects of ISG15 need
to be further explored, our current findings shed light on
the roles of ISG15 and provided information essential for its
development into an efficient gene therapeutic tool for the
treatment of IFN-𝛼-resistant HCC.

5. Conclusion
The main findings of the present study are as follows: (1) the
ectopically expressed ISG15 increases overall protein ubiquitination, upregulates p53 and p21 expression, and ultimately
enhances HCC cell apoptosis; (2) ISG15 either induced by
IFN-𝛼 or transiently overexpression localizes in both nucleus
and cytoplasm; and (3) overexpression of ISG15 could be
developed into an efficient therapeutic strategy for IFN-𝛼resistant HCC and other cancers.
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